TabsDetailsBasic DetailsDate Posted: Wednesday, December 20, 2017Status: CompleteMedical Product: adalimumab, certolizumab, etanercept, golimumab, infliximab, tumor necrosis factor (TNF) alpha inhibitorDescription: This report contains estimates of use of five tumor necrosis factor (TNF)-alpha inhibitors, etanercept, adalimumab, infliximab, certolizumab, and golimumab, that occurred during a pregnancy resulting in a liveborn delivery, or within 90 days prior to the estimated start of pregnancy. The query was run against the Sentinel Distributed Database (SDD) for the time period of January 1, 2004 to September 30, 2015. This request was distributed to 16 Data Partners on June 27, 2017. Read More Deliverables (1)Sentinel Modular Program Report: Anti-Tumor Necrosis Factor (TNF) Utilization Among Pregnant WomenAdditional InformationAdditional DetailsFDA Center: CDERTime Period: January 1, 2004 - September 30, 2015Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: Females 15-54 years of ageData Sources: Sentinel Distributed Database (SDD)
